Selected vulnerability of neurons in Huntington's disease suggests that alterations occur in a cellular process that is particularly critical for neuronal function. Supporting this idea, pathogenic Htt (polyQ-Htt) inhibits fast axonal transport (FAT) in various cellular and animal models of Huntington's disease (mouse and squid), but the molecular basis of this effect remains unknown. We found that polyQ-Htt inhibited FAT through a mechanism involving activation of axonal cJun N-terminal kinase (JNK). Accordingly, we observed increased activation of JNK in vivo in cellular and mouse models of Huntington's disease. Additional experiments indicated that the effects of polyQ-Htt on FAT were mediated by neuron-specific JNK3 and not by ubiquitously expressed JNK1, providing a molecular basis for neuron-specific pathology in Huntington's disease. Mass spectrometry identified a residue in the kinesin-1 motor domain that was phosphorylated by JNK3 and this modification reduced kinesin-1 binding to microtubules. These data identify JNK3 as a critical mediator of polyQ-Htt toxicity and provide a molecular basis for polyQ-Htt-induced inhibition of FAT.
Selected vulnerability of neurons in Huntington's disease suggests that alterations occur in a cellular process that is particularly critical for neuronal function. Supporting this idea, pathogenic Htt (polyQ-Htt) inhibits fast axonal transport (FAT) in various cellular and animal models of Huntington's disease (mouse and squid), but the molecular basis of this effect remains unknown. We found that polyQ-Htt inhibited FAT through a mechanism involving activation of axonal cJun N-terminal kinase (JNK). Accordingly, we observed increased activation of JNK in vivo in cellular and mouse models of Huntington's disease. Additional experiments indicated that the effects of polyQ-Htt on FAT were mediated by neuron-specific JNK3 and not by ubiquitously expressed JNK1, providing a molecular basis for neuron-specific pathology in Huntington's disease. Mass spectrometry identified a residue in the kinesin-1 motor domain that was phosphorylated by JNK3 and this modification reduced kinesin-1 binding to microtubules. These data identify JNK3 as a critical mediator of polyQ-Htt toxicity and provide a molecular basis for polyQ-Htt-induced inhibition of FAT.
Huntington's disease is an autosomal-dominant, adult-onset neurodegenerative disease 1 . Individuals with a single mutant huntingtin (HTT) gene develop symptoms in midlife with 100% penetrance. The mutation is a toxic gain of function, as the loss of a single gene has no phenotype and the Htt-null mouse is embryonic lethal 2 . The diseasecausing mutation is an expansion of a CAG trinucleotide repeat encoding a polyglutamine (polyQ) tract and polyQ expansions in other genes may also lead to adult-onset neurodegeneration, but the pathogenic mechanisms remain uncertain 2 . Several lines of evidence indicate that pathogenesis in Huntington's disease includes inhibition of FAT 3 . Although the consequences of FAT inhibition in neurons are well established, the mechanisms underlying inhibition of FAT by polyQ-Htt are unknown. Proposed mechanisms include wild-type Htt loss of function 4 , physical blockade by polyQ-Htt aggregates 5, 6 , sequestration of motor molecules 4, 6 and misregulation of FAT 3, 7, 8 .
We found no evidence for direct interactions of conventional kinesin and cytoplasmic dynein (CDyn) with wild-type Htt or polyQ-Htt in vivo. However, analysis of mouse and squid models of Huntington's disease showed that polyQ-Htt, but not wild-type Htt, increased JNK activity. Pharmacological and peptide inhibitors of JNK prevented inhibition of FAT by polyQ-Htt. To our surprise, only a subset of JNK isoforms inhibited FAT, with neuron-specific JNK3 selectively mimicking the effects of polyQ-Htt. In vitro phosphorylation and mass spectrometry studies showed that JNK3, but not ubiquitously expressed JNK1, phosphorylated Ser176 in the kinesin heavy chain (kinesin-1, KHC) motor domain. Consistent with this location, phosphorylation of kinesin-1 by JNK3 inhibited kinesin binding to microtubules and translocation along axons. Our data indicate that polyQ-Htt inhibits FAT by a mechanism involving axonal JNK3 activation and phosphorylation of kinesin-1.
RESULTS

Htt does not interact with microtubule-based motors
PolyQ-Htt inhibits FAT in various experimental systems, including Drosophila 4,5 , neuroblastoma cells 9,10 and isolated squid axoplasm 8 , but the molecular basis of this inhibition is unknown 3 . Interactions have been reported between exogenously overexpressed Htt and conventional kinesin 4 or various subunits of CDyn [9] [10] [11] . Alternatively, polyQexpansion has been proposed to affect Htt function as a scaffolding protein for molecular motors 9, 12 . However, interactions between endogenous wild-type Htt and molecular motors have not been evaluated. We tested interactions by immunoprecipitation and subcellular fractionation ( Fig. 1) , as described previously 13, 14 . To avoid overexpression-related artifacts, we used brain tissue from 14-monthold homozygous Htt Q109 knock-in mice and age-matched controls, which express polyQ-Htt or wild-type Htt at endogenous levels 15 . At this age, both polyQ-Htt-derived nuclear inclusions and insoluble aggregates are found in the brains of Htt Q109 knock-in mice 15 . © 2009 Nature America, Inc. All rights reserved.
Conventional kinesin is a heterotetramer composed of two heavy chains and two light chains (KLC) 13 . Antibodies recognizing kinesin-1 effectively immunoprecipitated kinesin-1 from detergent-soluble brain lysates independent of genotype ( Fig. 1a ). Kinesin-1 antibodies coimmunoprecipitated KLCs 13, 14 , but failed to co-immunoprecipitate either wild-type Htt or polyQ-Htt. Similarly, antibodies to dynein intermediate chains (DICs) co-immunoprecipitated dynein heavy chain (DHC) 16 , but did not immunoprecipitate wild-type Htt or polyQ-Htt ( Fig. 1a ). Conversely, antibodies to Htt immunoprecipitated Htt from both wild-type and homozygous Htt Q109 knockin mouse brain lysates, but kinesin-1, KLC, DIC and DHC could not be detected in Htt immunoprecipitates.
To detect substoichiometric amounts of Htt associated with conventional kinesin or CDyn, we performed three rounds of immunoprecipitation, which was sufficient to nearly deplete mouse brain lysates of kinesin-1 ( Fig. 1b) or DIC ( Supplementary Fig. 1 online) . As in previous studies, marked reductions in kinesin-1 and KLC levels occurred with each immunoprecipitation cycle 13, 14 . However, Htt levels remained unchanged after three immunoprecipitation cycles, regardless of genotype.
PolyQ-Htt has been reported to sequester molecular motors in detergent-insoluble aggregates when overexpressed 4,6 . To evaluate this at endogenous levels, we fractionated brain lysates from wild-type and homozygous Htt Q109 knock-in mice into detergent-soluble and detergent-insoluble fractions and analyzed partitioning of Htt and molecular motors by immunoblot ( Supplementary Fig. 1 ). Wild-type Htt and polyQ-Htt levels were comparable in detergent-soluble and detergent-insoluble fractions, but the bulk of kinesin-1, DHC and DIC were detergent soluble. Molecular motor levels were similar for wild-type and homozygous Htt Q109 knock-in mice. Thus, wild-type Htt and polyQ-Htt expressed at endogenous levels do not interact with molecular motors; thus, FAT inhibition associated with polyQ-Htt must result from a different mechanism.
JNK activity mediates FAT defects induced by polyQ-Htt
We assayed the effects of wild-type Htt and polyQ-Htt on FAT in isolated squid axoplasm 8 . Perfusion of wild-type Htt showed no effect ( Fig. 2a ), but perfusion of polyQ-Htt at a concentration 100-1,000fold lower than that of kinesin-1 (refs. 3,8) markedly inhibited both anterograde (kinesin dependent) and retrograde (CDyn dependent) FAT ( Fig. 2b) . In axoplasm, anterograde FAT of membrane-bounded organelles depends primarily on conventional kinesin 17 , which is regulated by phosphorylation 7, 18, 19 . Multiple kinase activities may be deregulated in Huntington's disease [20] [21] [22] and inhibition of FAT by pathogenic androgen receptor (polyQ-AR) depends on JNK activation in axoplasm 7 . This led us to evaluate the role of JNK in polyQ-Htt-induced inhibition of FAT. We assessed axoplasmic JNK activity in vitro using recombinant GST-cJun, a well-characterized JNK substrate 23 (Fig. 2c) . Incubation with axoplasm lysates produced a timedependent increase in cJun phosphorylation at JNK sites (serines 63 and 73), reflecting basal JNK activity in axoplasm. We validated the pharmacological properties of endogenous axoplasmic JNK with two JNK inhibitors (SP600125 and JNK inhibitor I peptide, JIP) 23 . SP600125 is a pharmacological inhibitor of JNK, and shows a 420-fold selectivity for JNK over a range of kinases 24 . JIP is a 20-amino acid peptide derived from a JNK-binding protein that selectively inhibits JNK, but not p38, activity 25 . Both SP600125 and JIP markedly inhibited cJun phosphorylation, suggesting that squid and mammalian JNKs have common pharmacological properties ( Fig. 2c) .
As with polyQ-AR 7 , perfusion of axoplasm with polyQ-Htt and either SP600125 (500 nM; Fig. 2d ) or JIP (100 nM; Fig. 2e ) blocked the effects of polyQ-Htt on FAT, suggesting that polyQ-Htt inhibition of FAT requires JNK activity. In cultured cells, pharmacological inhibitors of histone deacetylase (HDAC) have been reported to rescue defects in FAT induced by polyQ-Htt by increasing tubulin acetylation 26 . However, perfusion of polyQ-Htt with the HDAC6 inhibitor BC-6-25 (10 mM, Compound 2) 27 did not prevent inhibition of FAT by polyQ-Htt in axoplasm ( Fig. 2f) . Thus, inhibition of FAT by polyQ-Htt involves the activation of endogenous axonal JNK.
PolyQ-Htt expression increases JNK activity
Our vesicle motility and biochemical assays indicated that JNK activity mediates polyQ-Htt inhibition of FAT. JNK activation involves phosphorylation by upstream mitogen-activated protein kinase kinases (MKKs, typically MKK4/MKK7) 28 . We evaluated the effects of polyQ-Htt on JNK phosphorylation in cellular and animal models of Huntington's disease, using antibodies to total JNK (pan-JNK, phosphorylation independent) or to phosphorylated, catalytically active © 2009 Nature America, Inc. All rights reserved. JNKs (pJNK) ( Fig. 3) . We evaluated the effects of polyQ-Htt expression on JNK activation qualitatively after transient transfection ( Fig. 3a) . NSC34 mouse neuroblastoma cells were transfected with wild-type Htt (Q18) or polyQ-Htt (Q56) 29 . The expression of exogenous Htt constructs were similar to that of endogenous Htt, as shown by immunoblotting. Pan-JNK and pJNK antibodies recognized two major immunoreactive bands (p46 and p54), which corresponded to mammalian JNKs in NSC34 cell lysates and striatal mouse tissue ( Fig. 3a ,c) 30 . The expression levels for both pan-JNK immunoreactive bands were comparable in cells expressing wild-type Htt and polyQ-Htt. However, antibodies to pJNK showed a clear increase in p54 immunoreactivity in cells expressing polyQ-Htt ( Fig. 3a) , which is consistent with previous reports 20, 22, 31 . Differential activation of p54 and p46 JNKs led us to evaluate their identity using antibodies selective for JNK1, JNK2 and JNK3. Specificity was validated by immunoblotting with recombinant GST-tagged JNKs and brain lysates from mice lacking individual JNK genes 30 (Fig. 3b ). Antibodies to JNK1, 2 and 3 selectively recognized their target JNKs ( Fig. 3b ) and showed no immunoreactivity to brain lysates from mice lacking Mapk8 (JNK1), Mapk9 (JNK2) or Mapk10 (JNK3) (Fig. 3b) .
We examined JNK expression in striatal tissue from 8-monthold wild-type mice and heterozygous and homozygous Htt Q109 mice ( Fig. 3c) . Htt Q109 knock-in mice are asymptomatic at this age 15 . Phosphorylation of Akt at Ser473 ( Fig. 3c ) and pan-JNK © 2009 Nature America, Inc. All rights reserved. Figure 2 JNK inhibitors prevent polyQ-Htt-induced FAT inhibition. In vesicle motility assays in isolated axoplasm, we measured individual velocity (arrowheads) as a function of time. The dark arrowheads and black lines represent the anterograde kinesin-dependent FAT rates and the reversed gray arrowheads and gray lines indicate retrograde, cytoplasmic dynein-dependent FAT rates. In vitro translated Htt constructs were perfused as described previously 8 . (a) Perfusion of wild-type Htt did not affect FAT 8 . (b) Perfusion of polyQ-Htt inhibited both anterograde and retrograde FAT 8 . (c) Endogenous JNK activity in squid axoplasm was examined by in vitro phosphorylation assays. We observed a time-dependent increase in cJun phosphorylation at JNK sites (cJun S63/73) when GST-cJun was incubated with squid axoplasm lysates (axo). Phosphorylation of GST-cJun was completely inhibited by either SP600125 or JIP, two well-characterized JNK inhibitors. Antibody to GST revealed similar GST-cJun levels for each reaction (cJun total). (c) Striata from wild-type, heterozygous (hetero) and homozygous (homo) Htt Q109 mice showed similar total JNK (pan-JNK) levels regardless of genotype, whereas the amount of active JNK (pJNK) that was present was increased in Htt Q109 mice. Akt activation (pAkt) was similar for all mice. (d) Immunoblots using NSC34 (top) and mouse striatum (bottom) showed JNK1 comigrating with p46, whereas JNK2 and JNK3 comigrated with p54. (e) Quantitative analysis of immunoblots in c showed activation of both p54 and p46 JNK in Htt Q109 mice. pJNK/JNK ratios for JNK1 (p46) or JNK2/3 (p54) indicated that both JNK2/3 and JNK1 activity was higher in homozygous than in heterozygous Htt Q109 mice. JNK2/3 was activated to a greater extent than JNK1, suggesting differential activation of JNKs by polyQ-Htt. Error bars represent s.e.m. The differences between JNK2/3 activity in wild-type and Htt Q109 mice were significant (* indicates P r 0.01 in a pooled t test).
immunoreactivity did not change, regardless of genotype. However, pJNK immunoreactivity was substantially greater in lysates from heterozygous and homozygous Htt Q109 knock-in mice relative to wildtype mice (Fig. 3c) . Cortical lysates gave similar results (data not shown). The p54 and p46 forms of JNK were differentially activated, as observed in transfected cells. P54 showed greater increases in pJNK immunoreactivity than p46 in Htt Q109 mice relative to wild type in both striatum ( Fig. 3e ) and cortex (data not shown). Consistent with the autosomal dominance of Huntington's disease, JNK activation increased in both heterozygous and homozygous Htt Q109 mice, but activation was greater in homozygotes than in heterozygotes. Immunoreactivity corresponding to p54 and p46 in NSC34 and striatal lysates mainly corresponded to JNK2/3 and JNK1, respectively ( Fig. 3d) . We defined the activation ratio ( Fig. 3e) as being the ratio of pJNK/JNK immunoreactivities for JNK1 (p46) or JNK2/ 3 (p54). Both the JNK1 and JNK2/3 activation ratios were elevated in heterozygotes and homozygotes relative to wild-type brains. The JNK1 activity ratio in wild-type mice was 1.097 ± 0.146 (mean ± s.e.m.) and 1.527 ± 0.061 in homozygote and 1.342 ± 0.133 in heterozygote Htt Q109 mice (n ¼ 4 in all cases). The difference in JNK1 activity between wild-type and Htt Q109 homozygote mice was significant (P r 0.05 in a pooled t test), but the difference between wild-type and Htt Q109 heterozygote mice was not (P 4 0.05). The JNK2/3 activity ratio for wild-type mice was 0.242 ± 0.012 (mean ± s.e.m.) and 0.590 ± 0.055 for homozygote and 0.440 ± 0.035 for heterozygote mice (n ¼ 4 in all cases). The JNK2/3 activity ratio significantly increased in both homozygote and heterozygote Htt Q109 mice relative to wild-type mice (P r 0.01 in a pooled t test). Both JNK1 and JNK2/3 activity ratios were increased by polyQ-Htt, but polyQ-Htt had a greater effect on JNK2/3 than JNK1.
JNK3 mediates the effects of polyQ-Htt on FAT JNK2/3 is selectively activated in neurons by stress in the presence of constitutive JNK1 activity 32, 33 . Because we observed differential activation of JNKs (Fig. 3a,b) , we decided to evaluate the effects of specific JNK isoforms on FAT. SB203580 differentially affects JNK1 and JNK2/3 in vitro 24 . At a concentration of 10 mM, SB203580 preferentially inhibits JNK2/3 and inhibits JNK1 at a tenfold higher concentration 23 . Axoplasmic JNK activity was almost eliminated by 100 mM SB203580, but substantial JNK activity remained after treatment with 10 mM SB203580 (Fig. 4a) . However, 10 mM SB203580 completely prevented inhibition of FAT by polyQ-Htt ( Fig. 4b) , suggesting that the effects of polyQ-Htt involved JNK2 or JNK3. Notably, 10 mM SB203580 also prevented inhibition of FAT by polyQ-AR 7 . JNK isoforms were distinguished using biochemical approaches. JSAP1 is a scaffold protein regulating JNK activation 34 . We identified four JSAP1 isoforms (a, b, c and d), all of which contained a 17-amino acid JNK-binding domain homologous to JIP (Fig. 4c) . A 31-amino acid insert in JSAP1c/JSAP1d selectively reduces binding to JNK3 (ref. 34) . As a result, JSAP1d binds JNK3 with a lower affinity than JSAP1a and inhibits JNK3 less efficiently 34 . Recombinant JSAP1a (amino acids 115-233) and JSAP1d (amino acids 115-264) polypeptides were expressed and purified, and then perfused at 5 mM with polyQ-Htt ( Fig. 4d) . Perfusion of JSAP1a and JSAP1d alone had no effect on FAT (data not shown). As with JIP ( Fig. 2e) , perfusion of polyQ-Htt and JSAP1a completely prevented inhibition of FAT by polyQ-Htt (Fig. 4d) . In contrast, JSAP1d reduced, but did not eliminate, the effects of polyQ-Htt on FAT (Fig. 4e ), suggesting that JNK3 mediates the effects of polyQ-Htt on FAT.
We evaluated the effects of specific JNK isoforms on FAT in isolated axoplasm (Fig. 5) . The activity of recombinant JNKs was normalized in vitro using c-Jun as a substrate (data not shown). JNK1 (200 nM) did not affect FAT (Fig. 5a) , which is consistent with reports of constitutive JNK1 activity in neurons 32, 33 . JNK2 (100 nM) decreased anterograde FAT rates slightly (1.25 mm s À1 , compared with 1.6 mm s -1 for control buffer, P r 0.01, two-sample t test; Fig. 5b ), but did not affect retrograde FAT (Fig. 5d) . As with polyQ-Htt perfusion (Fig. 5d) , JNK3 (100 nM) inhibited both directions of FAT (Fig. 5c ). Quantitative analysis showed that JNK3 inhibited both anterograde (0.9 mm s -1 , compared with 1.6 mM s -1 in control buffer) and retrograde (1.25 mm s -1 , compared with 1.4 mm s -1 in control buffer) FAT (P r 0.01, two-sample t test), suggesting that JNK3 is principally responsible for the effects of polyQ-Htt on FAT.
JNK3 phosphorylates kinesin-1 at Ser176 JNK3 phosphorylates kinesin-1, but not KLCs 7 . Using liquid chromatography tandem mass spectrometry (LC/MS/MS), we mapped residues in kinesin-1 that were phosphorylated by JNK3 ( Fig. 6 and Supplementary Fig. 2 online) . Kinesin-1 constructs encompassing the first 584 amino acids of kinesin-1C (KHC 584 ) were phosphorylated in vitro with JNK3 (Fig. 6b) 7 and compared with nonphosphorylated KHC 584 . Phosphorylated polypeptides were directly digested with © 2009 Nature America, Inc. All rights reserved. Anterograde Retrograde Figure 4 The effects of polyQ-Htt on FAT are mediated by JNK3. SB203580 blocks the action of polyQ-AR on FAT 8 , but SB203580 is a poor inhibitor of JNK1 (the concentration needed to reduce kinase activity by 50% is Z 100 mM) and a good inhibitor of JNK2/3 (IC 50 E10 mM) 23 . (a) In vitro phosphorylation assays in axoplasm showed a dose-dependent inhibition of axoplasmic JNK activity by SB203580. Notably, substantial JNK activity remained in the presence of 10 mM SB203580, presumably representing endogenous JNK1 activity. (b) In contrast, vesicle motility assays in isolated squid axoplasm showed that the effects of polyQ-Htt on FAT were blocked by SB203580 at 10 mM, which is consistent with polyQ-Htt acting on JNK2/3. trypsin for LC/MS/MS analysis or for phosphopeptide enrichment by metal ion affinity chromatography (IMAC) 35 and LC/MS/MS analysis ( Supplementary Fig. 2 ). We identified mass spectrometry-generated peptides with the SEQUESTalgorithm. KHC 584 identity was confirmed by identification of multiple kinesin-1C peptides (coverage of 72%; Supplementary Fig. 2 ). We detected residual phosphorylation of several peptides (data not shown) and we identified a unique peptide corresponding to amino acids 173-188 with unequivocal evidence of phosphorylation by JNK3 using analysis of protease cleavage sites, mass spectra, cross correlation and delta correlation values ( Fig. 6a and Supplementary Fig. 2 ). Phosphatase treatment reduced the phosphorylated peak intensity compared with that of neighboring peaks (data not shown). This JNK3-phosphorylated peptide was in the kinesin-1c motor domain and contained two serines (Fig. 6a) . LC/MS/MS allowed us to precisely map the specific serine residue carrying the phosphorylation. Tandem mass spectrometry analysis by collision-induced dissociation indicated that phosphorylation occurred on Ser176, but not Ser175 ( Fig. 6 and Supplementary Fig. 2) . The presence of a proline residue adjacent to Ser176 (a hallmark of JNK substrates) supported our identification of Ser176 as the JNK3 phosphorylation site. Mass spectrometric analysis of JNK1-phosphorylated KHC 584 did not reveal phosphorylation at this site ( Supplementary Fig. 3 online) , consistent with the differential effects of JNK1 and JNK3 on FAT that we observed (Fig. 5a,c) . To confirm electrospray ionization-LC/MS/MS analysis, we used site-directed mutagenesis to substitute an alanine for either Ser175 or Ser176 of KHC 584 (KHC 584 -S175A and KHC 584 -S176A). Bacterially expressed mutant proteins were purified ( Fig. 6b) , phosphorylated in vitro with JNK3 and 32 P incorporation was analyzed by phosphorimaging. Phosphorylation of KHC 584 -S176A, but not KHC 584 -S175A, was reduced relative to wild-type KHC 584 by B30% (KHC 584 -wild-type; Fig. 6b ). Ser176 was conserved among squid, mouse and human kinesin-1 ( Supplementary Fig. 4 online). The amount of 32 P that was incorporated in KHC 584 -S176A was consistent with mass spectrometry findings of partial phosphorylation of KHC 584 in vitro at nonconserved residues outside of the motor domain (data not shown). We also detected Ser176 phosphorylation in kinesin-1 that was immunoprecipitated from mouse brain (data not shown). Together, these data identified Ser176 as a major kinesin-1 residue that is phosphorylated by JNK3.
Ser176 phosphorylation affects kinesin-1 function
The effects of polyQ-AR on FAT involve JNK activation, increase kinesin-1 phosphorylation and reduce microtubule binding of kinesin-1 (ref. 7) . Ser176 localized to loop 8, a sequence in the motor domain of kinesin-1 that has been implicated in kinesin-1 interaction with microtubules ( Supplementary Fig. 4 ) 36 , suggesting that its phosphorylation might affect kinesin-1 binding to microtubules. We transiently transfected NSC34 cells with wild-type Htt or polyQ-Htt (Fig. 3a) . The total amounts of kinesin-1 were comparable for nontransfected cells and cells expressing wild-type Htt or polyQ-Htt (Fig. 7a) . However, microtubule-binding assays using the nonhydrolysable ATP analog AMP-PNP 7 revealed a reduction in kinesin-1 binding to microtubules in polyQ-Htt-expressing cells relative to cells expressing wild-type Htt (Fig. 7a) . Similar effects were observed when using immortalized striatal cell lines derived from wild-type and Htt Q109 mice (data not shown). This was consistent with previous reports of reduced kinesin-1 binding to microtubules in cells expressing polyQ-AR 7 Figure 6 JNK3 phosphorylates kinesin-1 heavy chains at Ser176. (a) Using mass spectrometry, we identified a tryptic peptide in the motor domain of kinesin-1 (amino acids 173-188) that was phosphorylated by JNK3 (see also Supplementary Fig. 2 ). (b) Recombinant KHC 584 protein (WT) was incubated in the presence (+) or absence (À) of active JNK3 and 32 P-ATP and analyzed by SDS-PAGE. The ability of JNK3 to phosphorylate KHC 584 at S175 and S176 was also evaluated using KHC 584 -S175 and KHC 584 -S176A mutants. An autoradiogram ( 32 P) showed a marked reduction in the phosphorylation of the KHC 584 -S176A construct relative to wild type and KHC 584 -S175A (arrow). Coomassie blue (CB) staining indicated that each lane contained a comparable amount of KHC 584 . * indicates autophosphorylated JNK3. These results indicated that S176 is the main residue phosphorylated by JNK3. Recombinant KHC 584 was incubated with radiolabeled 32 P-gATP (100 mM) in the presence or absence of active JNK3 (Fig. 7b ) and then incubated with purified microtubules in the presence of 2 mM AMP-PNP or 2 mM ATP (to control for nonspecific pelleting, data not shown). We analyzed microtubule pellets and corresponding supernatants by immunoblot to visualize nonphosphorylated KHC 584 and by autoradiography to visualize JNK3-phosphorylated KHC 584 . In the presence of AMP-PNP, kinesin-1 forms a rigor structure with microtubules 13 . Virtually all nonphosphorylated KHC 584 partitioned with microtubules by immunoblot ( Fig. 7b) , but a large fraction of JNK3phosphorylated KHC 584 remained in the supernatant (Fig. 7b) , suggesting that phosphorylation of kinesin-1 by JNK3 inhibits kinesin-1 binding to microtubules. The presence of JNK3-phosphorylated KHC 584 in pellet fractions was consistent with residual phosphorylation occurring at residues outside of the motor domain. JNK-3 phosphorylation of kinesin-1 reduced binding to microtubules with AMP-PNP by B50% ( Supplementary Fig. 5 online) .
We assessed the effects of S176 phosphorylation on kinesin-1 motility in vivo by expressing GFP-tagged, truncated kinesin-1 constructs in cultured hippocampal neurons (Fig. 8) . When expressed in hippocampal cells, a GFP-tagged kinesin-1 construct (KHC 560 -GFP), which consists of the first 560 amino acids of wild-type KHC, selectively translocates to axon distal ends and accumulates there, but not in dendrites, indicating that this motor translocates preferentially along axonal microtubules 37 . KHC 560 -GFP-wild-type translocation is so efficient that little or no fluorescence can be detected in cell bodies or along axons 37 . To evaluate whether S176 phosphorylation affects kinesin translocation efficiency, we compared the localization of the phosphorylation-mimicking construct KHC 560 -GFP-S176E and its nonphosphorylatable counterpart KHC 560 -GFP-S176A with that of KHC 560 -GFP by quantitative fluorescence microscopy ( Fig. 8a-f ). Substantially less phosphomimetic KHC 560 -GFP-S176E construct accumulated at axonal tips than the KHC 560 -GFP construct (56 ± 2% versus 87 ± 3%, respectively, mean ± s.e.m., t test, P o 0.0001; Fig. 8g) , with more KHC 560 -GFP-S176E fluorescence being detected in cell bodies and only faint staining being seen in neurites (Fig. 8c) , which is what we would expect to observe if a substantial fraction of phosphomimetic kinesin-1 were distributed as a soluble protein.
Slightly less KHC 560 -GFP-S176A accumulated at axon tips (79% ± 2%) than KHC 560 -GFP, but accumulation of KHC 560 -GFP-S176A was still significantly higher than KHC 560 -GFP-S176E (t test, P o 0.0001; Fig. 8g ). Thus, a mutation of Ser176 that mimics phosphorylation reduces the efficiency of processive kinesin-1 translocation in cultured neurons.
DISCUSSION
Despite ubiquitous expression of Htt, neuronal cells are uniquely vulnerable to a toxic gain-of-function polyQ expansion, suggesting that processes that are critical for proper neuronal function and survival are selectively altered in Huntington's disease 3 . Axonal transport is essential for neurons because of their large size and complex functional architecture 3 . Notably, alterations in kinesin-1 function and regulation are associated with various human neuropathologies 3, 7, [38] [39] [40] .
Several reports link FAT inhibition to pathogenesis in Huntington's disease 4, 5, 8, 10 and other polyQ-expansion diseases 3, 7 . For example, overexpression of polyQ-Htt in cultured cells 10 and Drosophila 4,5 leads to reduced transport and accumulation of vesicular cargos in axons. PolyQ-Htt and polyQ-AR, two otherwise unrelated proteins, similarly inhibit FAT vesicle motility in isolated axoplasm independently of changes in gene transcription or aggregate formation 7, 8 . Such observations implicate FAT defects in Huntington's disease pathogenesis, which would partially explain the selective vulnerability of neurons in Huntington's disease and other polyQ-expanded diseases 3 .
Several models have been proposed to explain the inhibition of FAT that is induced by polyQ-Htt. Some require physical interactions © 2009 Nature America, Inc. All rights reserved. (a-f) Representative stage 3 neurons were transfected with GFP-tagged constructs encompassing the first 560 amino acids of kinesin-1 (KHC 560 , a,c,e) and mCherry, a soluble marker protein that diffuses throughout the cell (b,d,f). Scale bar represents 20 mm. Cells were fixed with formaldehyde and imaged 5 h after transfection. Wild-type (a) and nonphosphorylatable S176A mutant (S176A, e) constructs efficiently translocated so that they were localized almost exclusively at the axon tip. In contrast, a substantial fraction of the pseudophosphorylated S176 mutant (S176E, c) was found throughout the cell body. Arrows indicate the location of the neuronal cell bodies shown in b, d and f. (g) The percentage of total KHC 560 -GFP fluorescence localized at the axon tip was measured in cells expressing wild-type KHC 560 (n ¼ 22), KHC 560 S176E (n ¼ 33) or KHC 560 S176A (N ¼ 30). Significantly less KHC 560 S176E accumulated at axon tips with the wild-type construct (t test, P o 0.0001). Only marginally less KHC 560 S176A accumulated at the axon tip than the wild-type construct (t test, P E 0.05). Error bars indicate ± s.d.
Figure 7
PolyQ-Htt expression inhibits kinesin-1 binding to microtubules. (a) Lysates of NSC34 cells transfected with wild-type Htt or polyQ-Htt (as in Fig. 3a) were analyzed by immunoblot. The total levels (input) of KHC, DHC and tubulin (Tub) were comparable for untransfected (ctrl) cells and cells expressing wild-type Htt or polyQ-Htt. However, the fraction of kinesin-1 recovered in association with microtubules was reduced in lysates from polyQ-Htt-expressing cells when compared with untransfected and wild-type Htt-expressing cells. (b) Microtubule-binding assays using KHC 584 . Immunoblotting (WB) showed that nonphosphorylated KHC 584 was mainly recovered in association with microtubules (pellet). An autoradiogram ( 32 P) revealed that a substantial fraction of JNK3-phosphorylated KHC 584 remained in the supernatant.
between Htt and conventional kinesin 41 or CDyn subunits 9,10,12 .
PolyQ-Htt aggregates have been proposed to sequester molecular motors 4, 6 or to physically block FAT 5, 42 . Alternatively, it has been suggested that Htt mutations interfere with the normal functions of Htt as a scaffold linking molecular motors to transported cargoes [9] [10] [11] or that Htt mutations affect the subunit composition and function of molecular motors 12 . However, axoplasm experiments indicate that polyQ-Htt inhibits FAT at concentrations 100-1,000-fold lower than molecular motors, suggesting activation of enzymatic activities 3, 7, 8 . We used cell fractionation and immunoprecipitation to evaluate the interactions between Htt and molecular motors in brain tissue of wildtype and homozygous Htt Q109 mice. Regardless of genotype, we found similar levels of full-length Htt in detergent-soluble and detergentinsoluble fractions. In contrast, KHCs, KLCs, DIC and DHC levels were much higher in soluble fractions, suggesting that most molecular motors are not sequestered by polyQ-Htt. Unlike experiments involving Htt overexpression, immunoprecipitation failed to detect interactions between endogenous Htt and kinesin 41 or CDyn 12 (Fig. 1) .
Detection of KLCs in KHC immunoprecipitates and DHC in DIC
immunoprecipitates confirmed that physiologically relevant protein complexes were preserved 13, 14 . Such observations are inconsistent with models in which polyQ-Htt inhibits FAT through direct interactions with molecular motors.
Another model proposes that pathogenic polyQ-Htt activates the neuronal regulatory pathways that affect FAT 3 . Kinesin-1 and CDyn are regulated by phosphorylation of specific motor subunits 7, 18 . Kinase activities that regulate FAT, including GSK-3 (ref. 43) , Akt 44 and JNK 20, 22, 45 , are altered in Huntington's disease, and polyQ-AR activates JNK 7 . JNK inhibitors blocked the effects of polyQ-Htt on FAT and we found JNK activation in polyQ-Htt-expressing cells and Htt Q109 mice (Fig. 3) . JNK activation was more pronounced in homozygous Htt Q109 mice than in heterozygous littermates, but was increased in both, which is consistent with the autosomal dominant inheritance of Huntington's disease. JNK activation in presymptomatic Htt Q109 mice indicates that this change represents an early event in Huntington's disease.
Mammals have three JNK genes (Mapk8, Mapk9 and Mapk10) 46 . We observed that polyQ-Htt increased JNK2/3 activity more than JNK1 in Htt Q109 mice and polyQ-Htt-transfected cells (Fig. 3) , which is consistent with reports showing constitutive JNK1 activity and selective JNK2/3 activation in neurons with stress 32, 33 . This prompted us to examine the roles of specific JNK isoforms in mediating the effects of polyQ-Htt on FAT. SB203580 inhibited JNK2/3 at 10 mM, but JNK1 inhibition required Z100 mM SB203580 (ref. 23 ). Substantial JNK activity (presumably JNK1) remained in axoplasms treated with 10 mM SB203580 (Fig. 4a ), but 10 mM SB203580 prevented the effects of polyQ-Htt on FAT (Fig. 4b) , suggesting that the effects of polyQ-Htt on FAT involve JNK2/3. JSAP1 polypeptides further supported a role for JNK3, as JSAP1a, which inhibits all JNKs, preserved FAT effectively, but JSAP1d, with a 31-amino acid insert that selectively interferes with JNK3 binding 34 , did not ( Fig. 4d,e) .
To evaluate the role of individual JNKs on FAT, we examined the effects of active recombinant JNK1, JNK2 and JNK3 on FAT in axoplasm. Active JNK1 had no effect on FAT (Fig. 5a) , consistent with constitutive JNK1 activity in axons 32, 33 (Fig. 4a) . JNK2 produced a selective, moderate effect on anterograde FAT, but had no effect on retrograde FAT. In contrast, the effects of JNK3 on FAT paralleled those of polyQ-Htt by inhibiting both anterograde and retrograde FAT. The effects of polyQ-Htt on FAT appear to be primarily mediated by JNK3, although JNK2 may contribute. Notably, JNK3 is preferentially expressed in nervous tissues 47 and polyQ-Htt pathology is restricted to neurons.
To provide a molecular basis for FAT inhibition by JNK3, we identified relevant phosphorylation sites. Mass spectrometry mapped JNK3 phosphorylation of kinesin-1 to S176, a conserved residue in the motor domain ( Fig. 6a and Supplementary Figs. 2 and 3) . S176 was also modified in kinesin-1 that was immunoprecipitated from mouse brain (data not shown). Mutagenesis studies confirmed that JNK3 phosphorylated Ser176 (Fig. 6b ). JNK1 did not phosphorylate kinesin-1 at Ser176 ( Supplementary Fig. 3) , which is consistent with unique substrate preferences for JNK3 (ref. 48) . Ser176 was conserved among squid, mouse and human kinesin-1 ( Supplementary Fig. 4) , validating the squid axoplasm model. Collectively, these data demonstrate that JNK3 activity is elevated in the brains of Htt Q109 mice and axoplasm perfused with polyQ-Htt ( Figs. 3 and 4) , that JNK3 phosphorylates kinesin-1 at Ser176 ( Fig. 6 and Supplementary Figs. 2 and 3) , and that Ser176 modification is sufficient to inhibit trafficking of kinesin-1 (Fig. 8) . Antibodies selective for this epitope are under development and should allow us to quantify the fraction of neuronal kinesin-1 modified by JNK3 in Huntington's disease brains.
On the basis of Ser176's position in the motor domain 36 , we evaluated the effects of JNK3 phosphorylation on kinesin-1 binding to microtubules. JNK3-treated recombinant kinesin-1 and kinesin-1 in polyQ-Htt-transfected cells showed reduced binding to microtubules ( Fig. 7) . Furthermore, pseudo-phosphorylation at Ser176 markedly decreased kinesin-1 translocation in vivo (Fig. 8) , indicating that Ser176 phosphorylation interferes with kinesin-1 function.
Our results suggest that polyQ-Htt inhibits FAT by activation of axonal JNKs. In addition, JNK activation by polyQ-Htt is also consistent with changes in transcription 49 , and JNKs can be pro-apoptotic 30 ( Supplementary Fig. 6 online) . Notably, JNK3, but not JNK1, activity mediated the effects of polyQ-Htt on FAT, providing a partial explanation for selective neuronal vulnerability in Huntington's disease. JNK1 and JNK2 are ubiquitously expressed, whereas JNK3 is selectively expressed in brain and testes 47 . The identification of kinesin-1 as a JNK3 substrate provides a molecular basis for changes in FAT that is consistent with the neuron-selective pathology of polyQ-Htt.
In sum, neuronal JNK3 is activated by polyQ-Htt. JNK3 in turn phosphorylates kinesin-1, decreasing its ability to bind microtubules and move cargoes in FAT ( Fig. 8 and Supplementary Fig. 6 ). Identification of Ser176-phosphorylated kinesin-1 in normal mouse brain suggests that JNK3 is involved in a normal pathway for regulating kinesin and delivering specific membrane-bounded organelle cargoes to particular neuronal domains. Increased activation of this pathway by polyQ-Htt would lead to reductions in kinesin-based transport, deficits in synaptic and axonal function, and eventual dying-back neuronal degeneration 3 . Inhibition of JNK3 sufficed to prevent inhibition of FAT resulting from polyQ-Htt. Our results suggest that elevation of JNK activity and consequent inhibition of FAT may represent primary pathogenic events in Huntington's disease. Further studies should illuminate the molecular components mediating JNK activation by polyQ-Htt. Regardless, inhibition of JNK activity to protect FAT represents a promising therapeutic target for the treatment of Huntington's disease.
METHODS
Methods and any associated references are available in the online version of the paper at http://www.nature.com/natureneuroscience/.
Note: Supplementary information is available on the Nature Neuroscience website. 
ACKNOWLEDGMENTS
